AlzBiomarker

Dementia with Lewy Bodies vs Alzheimer's Disease: neurogranin (CSF)

Tools

Back to the Top

The levels of neurogranin in the cerebrospinal fluid of people with dementia with Lewy bodies appeared to be approximately 60 percent those of people with Alzheimer's disease (effect size = 0.58, p = 0.0008). Although only four studies contributed to the analysis and the total number of people with DLB was relatively small, the finding of less neurogranin in DLB was consistent across the handful of available studies. For comparison, CSF neruogranin in control subjects is also approximately 60 percent that of people with AD.

Loading data...

How to interpret a forest plot: Each individual effect size (ES) is a ratio of the mean biomarker level in one condition over the mean level in another condition. An ES equal to 1 means that the two conditions had identical mean values. An ES > 1 indicates higher levels in the first condition, whereas an ES < 1 indicates lower levels in the first condition. The overall ES, indicated by a black diamond, is a weighted average of the individual effect sizes. The weight of each data point was determined by the inverse of the variance and is reflected in the size of each square. The width of the overall ES diamond is determined by the 95 percent confidence interval. Data out of range of the scale, including ES and confidence intervals, are indicated by an arrowhead at the edge of the plot, when applicable. 

Version 3.0, July 2021.